Three Are Thwarted In Latest Lacosamide Gambit In US
Executive Summary
Three generics firms have failed in their latest attempt to invalidate a patent protecting UCB’s lacosamide-based Vimpat epilepsy brand until 2022.
You may also be interested in...
What’s Next? Five Things To Look Out For In March
This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.
AAM Weighs In On Supreme Court Challenge To UCB’s Lacosamide
Throwing its weight behind a US Supreme Court petition from Alembic, Mylan and Sun Pharma, local industry association the AAM has insisted that the top US court should correct the ‘lead compound test’ imposed by the Court of Appeals for the Federal Circuit and replace it with the statutory obviousness test.
Leading players lose US lacosamide appeal
Several of the world’s leading generics players, including Teva, Mylan, Apotex and Aurobindo, have failed to convince the US Court of Appeals that the sole US patent listed against UCB’s Vimpat (lacosamide) tablets is invalid. Reissued US drug-substance patent RE38,551 protects until 17 March 2022 the Vimpat epilepsy brand that experienced a 19% rise in US sales last year to C746 million (US$874 million).